Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized open-label study of F182112 versus investigator-preselected standard available therapy in relapsed/refractory multiple myeloma
CTR20261547Phase 3Active
- Sponsor
- Shandong New Era Pharmaceutical
- Start
- May 2026
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of F182112 in multiple myeloma (MM), sponsored by Shandong New Era Pharmaceutical. Started May 2026; status: active.
02
Drugs
F182112
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on CTR20261547.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261547.